Stockreport

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pillICOTY [Read more]